Hospital-acquired pneumonia (HAP) is the second
|
|
- Dustin Copeland
- 5 years ago
- Views:
Transcription
1 Guidelines and Critical Pathways for Severe Hospital-Acquired Pneumonia* Stanley Fiel, MD, FCCP Hospital-acquired pneumonia (HAP) is associated with high morbidity and mortality. Early, appropriate, and adequate empiric therapy can increase the chance of survival. In 1995, the American Thoracic Society provided guidelines for the initial treatment of immunocompetent HAP patients, which is one of the principal HAP management approaches available to physicians today. However, these guidelines have several important limitations, including a lack of recommendations for duration of therapy and no recognition of newer drugs such as cefepime, trovafloxacin, and meropenem. Furthermore, they fail to distinguish among similar compounds (ie, -lactam/ -lactamase inhibitor combinations) or to recommend specific antibiotics. The clinician using these guidelines needs to address local patterns of antimicrobial resistance, especially in ICUs. Effective computerized antibiotic management programs that incorporate information on local patterns of antimicrobial resistance can assist physicians in empiric therapy decision making, improve patient quality of care, and reduce medical costs. (CHEST 2001; 119:412S 418S) Key words: American Thoracic Society guidelines; antibiotic resistance; antibiotics; empiric therapy; hospital-acquired pneumonia; nosocomial pneumonia; patient quality of care Abbreviations: ATS American Thoracic Society; HAP hospital-acquired pneumonia; MRSA methicillin-resistant Staphylococcus aureus; MSSA methicillin-sensitive Staphylococcus aureus Hospital-acquired pneumonia (HAP) is the second most common nosocomial infection in the United States, but it has the highest morbidity and mortality. 1 Between one third and one half of all HAP patient deaths are directly attributable to the nosocomial infection, with mortality rates even higher if bacteremia or certain pathogens (eg, Pseudomonas aeruginosa or Acinetobacter) are involved. 1 Clinical studies have led to a consensus that empiric antibiotic therapy can reduce the HAP patient mortality rate and should be the preferred treatment strategy. 2 5 National guidelines for initial empiric treatment of HAP patients, such as those proposed by the American Thoracic Society (ATS) in 1995, are available to assist physicians in the management of their patients. 1 The ATS HAP management recommendations have provided helpful guidance since 1995, but the guidelines need updating. Furthermore, some gaps need to be addressed. For example, the original guidelines do not provide a suggested approach for incorporating information on local patterns of antibiotic resistance into the HAP management program of a given hospital. They do *From MCP Hahnemann School of Medicine, Philadelphia, PA. Correspondence to: Stanley Fiel, MD, FCCP, Professor of Medicine, MCP Hahnemann School of Medicine, 3300 Henry Ave, Philadelphia, PA not address the growing role of computers as the premiere vehicles for information dissemination, nor do they recognize how computer-assisted anti-infectives management programs can effectively assist clinicians in their decision making for HAP patients. 6,7 This article will review the 1995 ATS guidelines and key supporting clinical data for the initial empiric treatment of HAP patients, as well as some of the limitations of the ATS guidelines and the potential use of computers in patient care. Effective Therapy Reduces HAP Mortality Early, appropriate, and adequate antibiotic therapy has been found to reduce HAP patient mortality rates in clinical studies. A patient with a diagnosis of nosocomial pneumonia who receives appropriate antibiotic therapy is more than twice as likely to survive (Fig 1). 2 4 A more recent study 5 not only supports those data but further identifies the timing and adequacy of therapy as equally important factors. Patients with ventilator-associated pneumonia who receive early and adequate antibiotic therapy before completion of invasive diagnostic testing (bronchoscopy with BAL) have the lowest mortality rates, whether or not their HAP is subsequently confirmed by microbiological data (Fig 2). 5 How- 412S
2 Figure 1. Appropriate antibiotic therapy reduces HAP patient mortality rates. 2 4 ever, altering therapy after microbiological data become available has no effect on mortality rate. Patients who initially receive inadequate therapy that is changed in response to positive diagnostic test results have outcomes similar to those of patients who start and continue with inadequate therapy (Fig 2). 5 Since HAP diagnosis remains difficult and controversial and the timing of antibiotic therapy in relation to clinical recognition of the pneumonia is a major factor influencing mortality, initial empiric therapy is the best response to the challenge. 1,5,8,9 Review of ATS Guidelines In 1995, the ATS, following an extensive review of available information on HAP, published practical guidelines for the initial empiric treatment of HAP. 1 An HAP clinical management algorithm was developed using information on disease severity, the presence of risk factors for specific organisms, and time of onset of HAP ( 5 days after hospital admission). All these factors can influence the spectrum of likely HAP pathogens. 1 An overview of the Figure 2. Early and adequate antibiotic therapy reduces HAP patient mortality rates. 5 MID microbiological identification. ATS algorithm for HAP patient classification and treatment recommendations is presented in Figure 3. Patients who have mild-to-moderate HAP who are free of risk factors for specific pathogens, and patients with a diagnosis of early-onset severe HAP are presumed to be infected with one or more microorganisms of the core group (ATS 1 in Fig 3 and Table 1). This core group of pathogens includes the usual enteric Gram-negative bacilli suspects, as well as methicillin-sensitive Staphylococcus aureus (MSSA) and Streptococcus pneumoniae. 1 The ATS-recommended monotherapy for those HAP patients include second-generation cephalosporins, nonpseudomonal third-generation cephalosporins (cefotaxime or ceftriaxone), or a -lactam/ -lactamase inhibitor combination (ampicillin/sulbactam, ticarcillin/clavulanate, or piperacillin/tazobactam). In those patients allergic to penicillin, a fluoroquinolone (such as ciprofloxacin) may be employed if S pneumoniae has been excluded. Alternatively, aztreonam may be given as monotherapy or in combination with clindamycin. 1 The presence of specific risk factors (Table 2) in patients with mild-to-moderate HAP may signal the involvement of additional organisms such as Legionella, P aeruginosa, S aureus, or anaerobes in addition to the core pathogen(s) (ATS 2 in Fig 3 and Table 1). 1 These risk factors include patient-related conditions, infection control-related problems, and intervention-related alterations in host defenses or bacterial exposure. 1 The ATS-recommended therapy for this patient group is a combination of antiinfective agents directed toward the core group of pathogens and the specific risk factor-dependent organism. 1 However, in some situations, a -lactam/ -lactamase inhibitor combination may be sufficient to combat both the risk factor-associated organism as well as the core pathogen(s). 1 Although a core pathogen, S aureus is of special concern in HAP patients with diabetes, coma, head injury, renal failure, or recent influenza. 1 In those patients, the ATS guidelines suggest that additional treatment with vancomycin be considered until methicillinresistant S aureus (MRSA) is excluded. 1 The definition of severe HAP is essentially the same as that developed for severe community-acquired pneumonia (Table 3). 1,10 Patients with severe HAP generally require admission to an ICU. 1 Patients in the ICU for mechanical ventilation, or with severe sepsis or acute renal failure, also have increased risk of developing severe HAP. 1 If the onset of severe HAP is within 5 days of hospital admission, patients who do not present with additional pathogen-specific risk factors are likely to be infected with only the core organism(s) and should be treated accordingly (ATS 1 in Fig 3 and Table 1). 1 However, CHEST / 119 / 2/ FEBRUARY, 2001 SUPPLEMENT 413S
3 Figure 3. ATS algorithm for patient classification and treatment recommendations. Adapted from ATS 1995, with permission. 1 if severe HAP develops 5 days after hospitalization, several highly resistant Gram-negative organisms, such as P aeruginosa and Acinetobacter, are likely to be involved in addition to the core pathogen(s) (ATS 3 in Fig 3 and Table 1). 1 This group of additional pathogens should also be suspected in patients with severe HAP who present with risk factors (Table 2), regardless of time of onset. 1 For patients classified under ATS 3, the group strongly recommends the addition of antimicrobial agent(s) effective against P aeruginosa and Acinetobacter to a core antibiotic. 1 Antibiotics effective against such pathogens include the antipseudomonal penicillins, either singly or in combination with a -lactamase inhibitor, some third-generation cephalosporins, aztreonam, imipenem, aminoglycosides, and fluoroquinolones. 1 Despite these guidelines, if resistance to the quinolones has been a problem in a particular hospital, a combination of a -lactam/ lactamase inhibitor with an aminoglycoside instead of a fluoroquinolone may be preferred, even in patients with renal failure. Although the guidelines suggest initial treatment with a combination of antiinfectives, some patients may be able to complete Table 1 ATS HAP Organism Classification and Recommended Antibiotic Treatment Program* ATS Classification Organisms Antibiotics 1 Enteric Gram-negative bacilli: Enterobacter (nonpseudomonal) E coli Klebsiella Proteus Serratia marcescens Haemophilus influenzae MSSA S pneumoniae Third-generation nonpseudomonal cephalosporins (cefotaxime, ceftriaxone) if Enterobacter suspected, use in combination with another agent OR -Lactam/ -lactamase inhibitor combination (ampicillin/sulbactam, ticarcillin/clavulanate, piperacillin/tazobactam) If allergic to penicillin: Fluoroquinolone (ciprofloxacin) or clindamycin plus aztreonam 2 ATS 1 core organisms anaerobes ATS 1 core antibiotic regimen plus -lactam/ -lactamase inhibitor combination or clindamycin S aureus Vancomycin (until MRSA excluded) Legionella Macrolide (erythromycin) with or without rifampin P aeruginosa Treat as per ATS 3 3 ATS 1 core organisms Acinetobacter P aeruginosa Consider MRSA *Adapted from ATS Listed are the core organisms and antibiotic regimens. Aminoglycoside or ciprofloxacin plus one of the following: Antipseudomonal penicillin (piperacillin, ticarcillin) Antipseudomonal -lactam/ -lactamase inhibitor combination (piperacillin/tazobactam, ticarcillin/clavulanate) Aztreonam Imipenem Vancomycin 414S
4 Table 2 Risk Factors for Specific Pathogens (Noncore Pathogens) in HAP* Risk Factors Mild-to-moderate HAP (ATS 2) Witnessed aspiration, recent abdominal surgery 17,18 Coma, 19 head trauma, recent influenza, history of IV drug use, diabetes mellitus, renal failure High-dose steroids 20 Prolonged ICU stay, steroids, antibiotics, structural lung disease 21,22 Severe HAP (ATS 3) Antibiotics before onset of pneumonia plus mechanical ventilation 21,23 Antibiotics before onset of pneumonia plus mechanical ventilation; corticosteroid therapy, malnutrition, structural lung disease (bronchiectasis, cystic fibrosis), prolonged hospitalization 22 Antibiotics before onset of pneumonia; prolonged mechanical ventilation 24 *From ATS Development of severe HAP after 4 days of hospitalization is a risk factor for all the noncore pathogens shown. Pathogens Anaerobes S aureus Legionella P aeruginosa Acinetobacter P aeruginosa MRSA therapy with only one antimicrobial agent, especially if P aeruginosa and other resistant pathogens are not present and the patient is improving clinically. 1 Limitations of the ATS Guidelines The ATS guidelines for initial treatment of immunocompetent HAP patients, although thoroughly considered, have several important limitations. Controversy persists over the reliability of methods (eg, clinical examination vs invasive microbiological techniques) used to diagnose pneumonia and the role of invasive diagnostic procedures to quantitate microbial load in patients with clinical HAP. 1 Questions regarding who should be tested and how frequently, the use of specific bacterial counts for defining pneumonia, the possibility of false-negative results due to previous antibiotic therapy, and the reliability of results from the technically demanding invasive diagnostic procedure are still being debated. 1 The importance of invasive diagnostic procedures in the management of HAP patients is questionable, since clinical studies demonstrating the value of invasive diagnostic testing in place of clinical diagnosis are Table 3 ATS Definition of Severe HAP* Admission to the ICU Respiratory failure, defined as the need for mechanical ventilation or the need for 35% oxygen to maintain an arterial oxygen saturation 90% Rapid radiographic progression, multilobar pneumonia, or cavitation of a lung infiltrate Evidence of severe sepsis with hypotension and/or end-organ dysfunction: Shock (systolic BP 90 mm Hg, or diastolic BP 60 mm Hg) Requirement for vasopressors for 4h Urine output 20 ml/h or total urine output 80 ml in 4 h (unless another explanation is available) Acute renal failure requiring dialysis *Adapted from ATS 1995, 1 with permission. lacking and because of the proven benefit of initiating empiric therapy before the causative agent(s) are cultured and identified. 1 The optimal length of antibiotic therapy for HAP needs to be addressed in clinical studies. 1 Except for certain situations (eg, the presence of multilobar involvement, malnutrition, severe debilitation, cavitation, a necrotizing Gram-negative bacillus pneumonia, or an MSSA or Haemophilus influenzae pneumonia), the ATS guidelines provide no recommendation on the duration of therapy. 1 The ATS guidelines of 1995 have several limitations in the discussion of antibiotics and recommended therapies. Since the guidelines were published in 1995 without update, they do not include newer therapies (eg, cefepime, meropenem, and trovafloxacin) that may be effective and/or associated with less resistance. For those antibiotic families containing multiple compounds (eg, cephalosporins, -lactam/ -lactamase inhibitor combinations), the ATS made no recommendations or attempts to distinguish among the available options, either within any particular antibiotic group or between groups, unless supported by clinical study data. 1 The ATS guidelines were also based on the expected antimicrobial spectra of commonly employed antibiotics, while acknowledging that few clinical trials have evaluated the efficacy or superiority of their suggested protocols. 1 However, important data from recent studies should be evaluated and the information incorporated into the guidelines. The heavy use of third-generation cephalosporins and aztreonam is associated with the emergence of extended-spectrum -lactamases, resulting in significant transferable drug-resistance problems. 11 In contrast, drugs like piperacillin/tazobactam, which may be substituted for a cephalosporin in the treatment of patients with moderate-to-severe HAP, are not associated with extended-spectrum -lactamase emergence. 11 Piperacillin/tazobactam has emerged CHEST / 119 / 2/ FEBRUARY, 2001 SUPPLEMENT 415S
5 as an important broad-spectrum antibiotic combination that is active against Gram-positive aerobes, including enterococci, Gram-negative aerobes, and anaerobes and may offer the convenience of monotherapy in certain situations. This -lactam/ -lactamase inhibitor combination drug coupled with tobramycin has been shown in clinical trials to have greater efficacy and a more favorable bacteriologic response for both unimicrobial and polymicrobial pneumonias than ceftazidime plus tobramycin. 12 Those favorable responses translated into significantly less mortality in the piperacillin/tazobactam therapy group than in the ceftazidime group. Studies since the 1980s have well documented the increase in antibiotic resistance and nosocomial outbreaks worldwide In hospitals in the United States, Canada, and Latin America, the most common bacterial pathogens associated with bloodstream infection were S aureus, Escherichia coli, and coagulase-negative staphylococci; the most frequent Gram-negative organisms were E coli, Klebsiella species, and P aeruginosa (Table 4). 16 Of special concern are antibiotic-resistant microorganisms encountered in the ICU. A recent analysis of antibiotic susceptibility among aerobic Gram-negative bacilli in European ICUs indicated significant resistance to multiple compounds and the need for more effective strategies to control the selection and spread of resistant organisms. 15 These findings highlight the need for a faster means of incorporating information on local patterns of resistance and patterns in particular hospital services (eg, the ICU or burn unit) into the global framework of the guidelines. This step is vital in order to maintain effective antimicrobial therapies and is of special concern for HAP and ICU patients because of their high proportion of mortalities. Computer-Assisted Anti-infectives Management Programs Many hospitals have established their own surveillance programs to monitor pathogen distribution and resistance patterns. Computer-assisted antibiotic management programs can facilitate the dissemination of such information to physicians for immediate use in therapy decision making. One community teaching hospital employed a computer-assisted antibiotic management program with guidelines devised by local clinicians for a 7-year period and found antibiotic use had improved while costs were reduced, and adverse drug reactions were minimized while the emergence of antibiotic-resistant pathogens stabilized. 6 In a follow-up study, in which a 2-year preintervention period was compared with a 1-year intervention term, the use of a computerized anti-infectives management program was found to improve the quality of patient care and reduce costs. 7 The study Table 4 Frequency of Occurrence of Bacterial Pathogens Associated With Bloodstream Infection in Medical Centers in the United States, Canada, and Latin America* Organisms Total (n 9,519) United States (n 6,150) Canada (n 1,727) Latin America (n 1,642) S aureus 2,151 (22.6) 1,467 (23.9) 348 (20.2) 336 (20.5) E coli 1,751 (18.4) 1,141 (18.6) 329 (19.1) 281 (12.1) Coagulase-negative 1,256 (13.2) 778 (12.7) 227 (13.1) 250 (15.2) staphylococci Enterococcus species 794 (8.3) 589 (9.6) 157 (9.1) 48 (2.9) Klebsiella species 765 (8.0) 473 (7.7) 123 (7.1) 169 (10.3) S pneumoniae 475 (5.0) 341 (5.5) 102 (5.9) 32 (1.9) P aeruginosa 451 (4.7) 276 (4.5) 83 (4.8) 92 (5.6) Enterobacter species 399 (4.2) 232 (3.8) 71 (4.1) 96 (4.8) -Hemolytic streptococci 307 (3.2) 225 (3.7) 57 (3.3) 25 (1.5) Acinetobacter species 206 (2.2) 100 (1.6) 19 (1.1) 87 (5.3) Viridans group streptococci 154 (1.6) 68 (1.1) 71 (4.1) 15 (0.9) Serratia species 136 (1.4) 68 (1.1) 32 (1.9) 36 (2.2) Proteus mirabilis 122 (1.3) 88 (1.4) 18 (1.0) 16 (1.0) Salmonella species 93 (1.0) 33 (0.5) 10 (0.6) 50 (3.0) Citrobacter species 76 (0.8) 50 (0.8) 16 (0.9) 10 (0.6) Stenotrophomonas maltophilia 69 (0.7) 43 (0.7) 11 (0.6) 15 (0.9) Pantoea agglomerans 44 (0.5) 25 (0.4) 8 (0.5) 11 (0.7) Haemophilus species 27 (0.3) 20 (0.3) 7 (0.4) 0 (0.0) Morganella morganii 26 (0.3) 16 (0.2) 6 (0.3) 4 (0.2) Corynebacterium species 20 (0.2) 14 (0.2) 3 (0.2) 3 (0.1) *Data are presented as No. of isolates (% of total). Adapted from Diekema et al 16 with permission. 416S
6 populations for both periods were similar, with 10% of patients having respiratory tract infections. Although the distribution of pathogens did not vary between periods, there were increases in bacteremias and infections by P aeruginosa and enterococcal species and decreases in infections caused by S aureus and E coli during the intervention period. 7 Other outcomes showing significant changes during the intervention period included the following: percentage of patients receiving anti-infective agents (increased), number of adverse drug reactions (decreased), number of susceptibility-mismatch alerts (decreased), number of drug-allergy alerts (decreased), number of excessive-drug-dosage alerts (decreased), and average number of days receiving an excessive anti-infective dosage (decreased). 7 During the intervention period, patients received an average of 4.7 fewer doses of anti-infective agents (p 0.042), had an average decrease of $81 in the cost of anti-infective agents (p 0.079), and received an excessive dose of an anti-infective for an average of 2.9 fewer days. 7 Implementation of the program also had a significant impact on factors affecting cost. A comparison of means adjusted for age, sex, computer severity index score on admission to unit, medical service, and mortality indicated reductions in the number of doses of anti-infective agents, the cost of the anti-infective agents, total length of stay, and total cost of hospitalization. 7 Physicians were permitted to override the management program s suggestions, and all those who overrode had valid reasons for doing so. However, when suggestions were overridden, cost savings were negated, sometimes to the point to which preintervention-period costs were less. 7 Summary Despite our improved understanding of the pathogenesis, diagnosis, therapy, and prevention of HAP, it remains the leading cause of mortality stemming from nosocomial infections. Early, adequate, and appropriate empiric antibiotic therapy can save the lives of more than half of all HAP patients. The 1995 ATS guidelines for initial empiric treatment of HAP are perhaps the best currently available. However, they are limited in several important ways, most notably in their failure to address the need to incorporate information on local patterns of antibiotic resistance. Computer-assisted antibiotic management programs can effectively aid clinicians in their decision-making processes, resulting in improved patient quality of care and reduced medical costs. Appendix Dr. Stanley Fiel: In a recent JAMA article written by Hanberger et al, 15 antibiotic susceptibility among aerobic Gram-negative bacilli was looked at in ICUs in five European countries. Resistance was either relatively high or higher than I would have expected in this particular group of European countries. What are some of the reasons for this observation that you may know about through your surveillance? Dr. Ronald Jones: These data come out of the Merck ICU program, the same as the one in the United States. It is composed of groups of 10 to 20 to 30 laboratories in individual nations. The database is actually old; 1993 to 1995 data points are in the article. Those rates look fairly comparable with what was coming out of national programs during that same period of time. I think those rates are relatively accurate, and they were using a reliable surveillance method that focused only on Gram-negatives during that surveillance. There are a lot of differences in antibiotic use among those nations. I think it is more controlled in Sweden. References 1 American Thoracic Society. Hospital-acquired pneumonia in adults: diagnosis, assessment of severity, initial antimicrobial therapy, and preventative strategies. Am J Respir Crit Care Med 1995; 153: Moore RD, Smith CR, Lietman PS. Association of aminoglycoside plasma levels with therapeutic outcome in Gramnegative pneumonia. Am J Med 1984; 77: Celis R, Torres A, Gatell JM, et al. Nosocomial pneumonia: a multivariate analysis of risk and prognosis. Chest 1988; 93: Torres A, Aznar R, Gatell JM, et al. Incidence, risk, and prognosis factors of nosocomial pneumonia in mechanically ventilated patients. Am Rev Respir Dis 1990; 142: Luna CM, Vujacich P, Niederman MS, et al. Impact of BAL data on the therapy and outcome of ventilator-associated pneumonia. Chest 1997; 111: Pestotnik SL, Classen DC, Evans RS, et al. Implementing antibiotic practice guidelines through computer-assisted decision support: clinical and financial outcomes. Ann Intern Med 1996; 124: Evans RS, Pestotnik SL, Classen DC, et al. A computerassisted management program for antibiotics and other antiinfective agents. N Engl J Med 1998; 338: Fagon J-Y, Chastre J, Hance AJ, et al. Detection of nosocomial lung infection in ventilated patients: use of a protected specimen brush and quantitative culture techniques in 147 patients. Am Rev Respir Dis 1988; 138: Papazian L, Thomas P, Garbe L, et al. Bronchoscopic or blind sampling techniques for the diagnosis of ventilator-associated pneumonia. Am J Respir Crit Care Med 1995; 152: American Thoracic Society. Guidelines for the initial management of adults with community-acquired pneumonia: diagnosis, assessment of severity, and initial antimicrobial therapy. Am Rev Respir Dis 1993; 148: Gold HS, Moellering RC Jr. Antimicrobial-drug resistance. N Engl J Med 1996; 335: CHEST / 119 / 2/ FEBRUARY, 2001 SUPPLEMENT 417S
7 12 Joshi M, Bernstein J, Solomkin J, et al. Piperacillin/tazobactam plus tobramycin versus ceftazidime plus tobramycin for the treatment of patients with nosocomial lower respiratory tract infection: Piperacillin/tazobactam Nosocomial Pneumonia Study Group. J Antimicrob Chemother 1999; 43: Zervos MJ, Terpenning MS, Schaberg DR, et al. High-level aminoglycoside-resistant enterococci. Arch Intern Med 1987; 147: Wiener J, Quinn JP, Bradford PA, et al. Multiple antibioticresistant Klebsiella and Escherichia coli in nursing homes. JAMA 1999; 281: Hanberger H, Garcia-Rodriguez J-A, Gobernado M, et al. Antibiotic susceptibility among aerobic Gram-negative bacilli in intensive care units in 5 European countries. JAMA 1999; 281: Diekema DJ, Pfaller MA, Jones RN, et al. Survey of bloodstream infections due to Gram-negative bacilli: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, and Latin America for the SENTRY Antimicrobial Surveillance Program, Clin Infect Dis 1999; 29: Bartlett JG, O Keefe P, Tally FP, et al. Bacteriology of hospital-acquired pneumonia. Arch Intern Med 1986; 146: Mier L, Dreyfuss D, Darchy B, et al. Is penicillin G an adequate initial treatment for aspiration pneumonia? A prospective evaluation using a protected specimen brush and quantitative cultures. Intensive Care Med 1993; 19: Rello J, Quintana E, Ausina V, et al. Risk factors for Staphylococcus aureus nosocomial pneumonia in critically ill patients. Am Rev Respir Dis 1990; 142: Carratala J, Gudiol F, Pallares R, et al. Risk factors for nosocomial Legionella pneumophila pneumonia. Am J Respir Crit Care Med 1994; 149: Rello J, Ausina V, Ricart M, et al. Impact of previous antimicrobial therapy on the etiology and outcome of ventilator-associated pneumonia. Chest 1993; 104: Niederman MS. Gram-negative colonization of the respiratory tract: pathogenesis and clinical consequences. Semin Respir Infect 1990; 5: Fagon J-Y, Chastre J, Domart Y, et al. Nosocomial pneumonia in patients receiving continuous mechanical ventilation. Am Rev Respir Dis 1989; 139: Rello J, Torres A, Ricart M, et al. Ventilator-associated pneumonia by Staphylococcus aureus: comparison of methicillin-resistant and methicillin-sensitive episodes. Am J Respir Crit Care Med 1994; 150: S
Appropriate antimicrobial therapy in HAP: What does this mean?
Appropriate antimicrobial therapy in HAP: What does this mean? Jaehee Lee, M.D. Kyungpook National University Hospital, Korea KNUH since 1907 Presentation outline Empiric antimicrobial choice: right spectrum,
More informationControl emergence of drug-resistant. Reduce costs
...PRESENTATIONS... Guidelines for the Management of Community-Acquired Pneumonia Richard E. Chaisson, MD Presentation Summary Guidelines for the treatment of community-acquired pneumonia (CAP) have been
More informationConcise Antibiogram Toolkit Background
Background This toolkit is designed to guide nursing homes in creating their own antibiograms, an important tool for guiding empiric antimicrobial therapy. Information about antibiograms and instructions
More informationManagement of Hospital-acquired Pneumonia
Management of Hospital-acquired Pneumonia Adel Alothman, MB, FRCPC, FACP Asst. Professor, COM, KSAU-HS Head, Infectious Diseases, Department of Medicine King Abdulaziz Medical City Riyadh Saudi Arabia
More information4/3/2017 CLINICAL PEARLS: UPDATES IN THE MANAGEMENT OF NOSOCOMIAL PNEUMONIA DISCLOSURE LEARNING OBJECTIVES
CLINICAL PEARLS: UPDATES IN THE MANAGEMENT OF NOSOCOMIAL PNEUMONIA BILLIE BARTEL, PHARMD, BCCCP APRIL 7 TH, 2017 DISCLOSURE I have had no financial relationship over the past 12 months with any commercial
More information2012 ANTIBIOGRAM. Central Zone Former DTHR Sites. Department of Pathology and Laboratory Medicine
2012 ANTIBIOGRAM Central Zone Former DTHR Sites Department of Pathology and Laboratory Medicine Medically Relevant Pathogens Based on Gram Morphology Gram-negative Bacilli Lactose Fermenters Non-lactose
More informationSHC Clinical Pathway: HAP/VAP Flowchart
SHC Clinical Pathway: Hospital-Acquired and Ventilator-Associated Pneumonia SHC Clinical Pathway: HAP/VAP Flowchart v.08-29-2017 Diagnosis Hospitalization (HAP) Pneumonia develops 48 hours following: Endotracheal
More informationThe International Collaborative Conference in Clinical Microbiology & Infectious Diseases
The International Collaborative Conference in Clinical Microbiology & Infectious Diseases PLUS: Antimicrobial stewardship in hospitals: Improving outcomes through better education and implementation of
More informationMeasure Information Form
Release Notes: Measure Information Form Version 3.0b **NQF-ENDORSED VOLUNTARY CONSENSUS STANDARDS FOR HOSPITAL CARE** Measure Set: Pneumonia (PN) Performance Measure Identifier: Measure Information Form
More information4 th and 5 th generation cephalosporins. Naderi HR Associate professor of Infectious Diseases
4 th and 5 th generation cephalosporins Naderi HR Associate professor of Infectious Diseases Classification Forth generation: Cefclidine, cefepime (Maxipime),cefluprenam, cefoselis,cefozopran, cefpirome
More informationOriginal Articles. K A M S W Gunarathne 1, M Akbar 2, K Karunarathne 3, JRS de Silva 4. Sri Lanka Journal of Child Health, 2011; 40(4):
Original Articles Analysis of blood/tracheal culture results to assess common pathogens and pattern of antibiotic resistance at medical intensive care unit, Lady Ridgeway Hospital for Children K A M S
More informationUCSF guideline for management of suspected hospital-acquired or ventilatoracquired pneumonia in adult patients
Background/methods: UCSF guideline for management of suspected hospital-acquired or ventilatoracquired pneumonia in adult patients This guideline establishes evidence-based consensus standards for management
More information2015 Antibiotic Susceptibility Report
Citrobacter freundii Enterobacter aerogenes Enterobacter cloacae Escherichia coli Haemophilus influenzenza Klebsiella oxytoca Klebsiella pneumoniae Proteus mirabilis Pseudomonas aeruginosa Serratia marcescens
More informationC&W Three-Year Cumulative Antibiogram January 2013 December 2015
C&W Three-Year Cumulative Antibiogram January 213 December 215 Division of Microbiology, Virology & Infection Control Department of Pathology & Laboratory Medicine Contents Comments and Limitations...
More informationRCH antibiotic susceptibility data
RCH antibiotic susceptibility data The following represent RCH antibiotic susceptibility data from 2008. This data is used to inform antibiotic guidelines used at RCH. The data includes all microbiological
More informationTable 1. Commonly encountered or important organisms and their usual antimicrobial susceptibilities.
Table 1. Commonly encountered or important organisms and their usual antimicrobial susceptibilities. Gram-positive cocci: Staphylococcus aureus: *Resistance to penicillin is almost universal. Resistance
More information2016 Antibiotic Susceptibility Report
Fairview Northland Medical Center and Elk River, Milaca, Princeton and Zimmerman Clinics 2016 Antibiotic Susceptibility Report GRAM-NEGATIVE ORGANISMS 2016 Gram-Negative Non-Urine The number of isolates
More informationAntimicrobial Susceptibility Testing: Advanced Course
Antimicrobial Susceptibility Testing: Advanced Course Cascade Reporting Cascade Reporting I. Selecting Antimicrobial Agents for Testing and Reporting Selection of the most appropriate antimicrobials to
More informationMAGNITUDE OF ANTIMICROBIAL USE. Antimicrobial Stewardship in Acute and Long Term Healthcare Facilities: Design, Implementation and Challenges
Antimicrobial Stewardship in Acute and Long Term Healthcare Facilities: Design, Implementation and Challenges John A. Jernigan, MD, MS Division of Healthcare Quality Promotion Centers for Disease Control
More informationMercy Medical Center Des Moines, Iowa Department of Pathology. Microbiology Department Antibiotic Susceptibility January December 2016
Mercy Medical Center Des Moines, Iowa Department of Pathology Microbiology Department Antibiotic Susceptibility January December 2016 These statistics are intended solely as a GUIDE to choosing appropriate
More information2010 ANTIBIOGRAM. University of Alberta Hospital and the Stollery Children s Hospital
2010 ANTIBIOGRAM University of Alberta Hospital and the Stollery Children s Hospital Medical Microbiology Department of Laboratory Medicine and Pathology Table of Contents Page Introduction..... 2 Antibiogram
More information2009 ANTIBIOGRAM. University of Alberta Hospital and the Stollery Childrens Hospital
2009 ANTIBIOGRAM University of Alberta Hospital and the Stollery Childrens Hospital Division of Medical Microbiology Department of Laboratory Medicine and Pathology 2 Table of Contents Page Introduction.....
More informationAntimicrobial susceptibility
Antimicrobial susceptibility PATTERNS Microbiology Department Canterbury ealth Laboratories and Clinical Pharmacology Department Canterbury District ealth Board March 2011 Contents Preface... Page 1 ANTIMICROBIAL
More informationSepsis is the most common cause of death in
ADDRESSING ANTIMICROBIAL RESISTANCE IN THE INTENSIVE CARE UNIT * John P. Quinn, MD ABSTRACT Two of the more common strategies for optimizing antimicrobial therapy in the intensive care unit (ICU) are antibiotic
More informationUpdate on Resistance and Epidemiology of Nosocomial Respiratory Pathogens in Asia. Po-Ren Hsueh. National Taiwan University Hospital
Update on Resistance and Epidemiology of Nosocomial Respiratory Pathogens in Asia Po-Ren Hsueh National Taiwan University Hospital Ventilator-associated Pneumonia Microbiological Report Sputum from a
More informationTreatment Guidelines and Outcomes of Hospital- Acquired and Ventilator-Associated Pneumonia
SUPPLEMENT ARTICLE Treatment Guidelines and Outcomes of Hospital- Acquired and Ventilator-Associated Pneumonia Antoni Torres, Miquel Ferrer, and Joan Ramón Badia Pneumology Department, Clinic Institute
More informationInt.J.Curr.Microbiol.App.Sci (2017) 6(3):
International Journal of Current Microbiology and Applied Sciences ISSN: 2319-7706 Volume 6 Number 3 (2017) pp. 891-895 Journal homepage: http://www.ijcmas.com Original Research Article https://doi.org/10.20546/ijcmas.2017.603.104
More informationNational Clinical Guideline Centre Pneumonia Diagnosis and management of community- and hospital-acquired pneumonia in adults
National Clinical Guideline Centre Antibiotic classifications Pneumonia Diagnosis and management of community- and hospital-acquired pneumonia in adults Clinical guideline 191 Appendix N 3 December 2014
More informationNQF-ENDORSED VOLUNTARY CONSENSUS STANDARDS FOR HOSPITAL CARE. Measure Information Form
Last Updated: Version 3.2a NQF-ENDORSED VOLUNTARY CONSENSUS STANDARDS FOR HOSPITAL CARE Measure Set: Pneumonia (PN) Performance Measure Identifier: Measure Information Form Organization Set Measure ID#
More informationHospital-acquired pneumonia: microbiological data and potential adequacy of antimicrobial regimens
Eur Respir J 2002; 20: 432 439 DOI: 10.1183/09031936.02.00267602 Printed in UK all rights reserved Copyright #ERS Journals Ltd 2002 European Respiratory Journal ISSN 0903-1936 Hospital-acquired pneumonia:
More informationGUIDELINES FOR THE MANAGEMENT OF COMMUNITY-ACQUIRED PNEUMONIA IN ADULTS
Version 3.1 GUIDELINES FOR THE MANAGEMENT OF COMMUNITY-ACQUIRED PNEUMONIA IN ADULTS Date ratified June 2008 Updated March 2009 Review date June 2010 Ratified by Authors Consultation Evidence base Changes
More informationNosocomial Infections: What Are the Unmet Needs
Nosocomial Infections: What Are the Unmet Needs Jean Chastre, MD Service de Réanimation Médicale Hôpital Pitié-Salpêtrière, AP-HP, Université Pierre et Marie Curie, Paris 6, France www.reamedpitie.com
More informationRecommendations for Implementation of Antimicrobial Stewardship Restrictive Interventions in Acute Hospitals in Ireland
Recommendations for Implementation of Antimicrobial Stewardship Restrictive Interventions in Acute Hospitals in Ireland A report by the Hospital Antimicrobial Stewardship Working Group, a subgroup of the
More informationPneumonia Antibiotic Guidance for Adults PAGL Inclusion Approved at January 2017 PGC
Pneumonia Antibiotic Guidance for Adults PAGL Inclusion Approved at January 2017 PGC APPROVED BY: Policy and Guidelines Committee TRUST REFERENCE: B9/2009 AWP Ref: AWP61 Date (approved): July 2008 REVIEW
More information2015 Antibiogram. Red Deer Regional Hospital. Central Zone. Alberta Health Services
2015 Antibiogram Red Deer Regional Hospital Central Zone Alberta Health Services Introduction. This antibiogram is a cumulative report of the antimicrobial susceptibility rates of common microbial pathogens
More informationAntimicrobial Pharmacodynamics
Antimicrobial Pharmacodynamics November 28, 2007 George P. Allen, Pharm.D. Assistant Professor, Pharmacy Practice OSU College of Pharmacy at OHSU Objectives Become familiar with PD parameters what they
More informationCONTAGIOUS COMMENTS Department of Epidemiology
VOLUME XXIII NUMBER 1 July 2008 CONTAGIOUS COMMENTS Department of Epidemiology Bugs and Drugs Elaine Dowell, SM (ASCP), Marti Roe SM (ASCP), Ann-Christine Nyquist MD, MSPH Are the bugs winning? The 2007
More informationThe β- Lactam Antibiotics. Munir Gharaibeh MD, PhD, MHPE School of Medicine, The University of Jordan November 2018
The β- Lactam Antibiotics Munir Gharaibeh MD, PhD, MHPE School of Medicine, The University of Jordan November 2018 Penicillins. Cephalosporins. Carbapenems. Monobactams. The β- Lactam Antibiotics 2 3 How
More informationAerobic bacterial infections in a burns unit of Sassoon General Hospital, Pune
Original article Aerobic bacterial infections in a burns unit of Sassoon General Hospital, Pune Patil P, Joshi S, Bharadwaj R. Department of Microbiology, B.J. Medical College, Pune, India. Corresponding
More informationAntibiotic Abyss. Discussion Points. MRSA Treatment Guidelines
Antibiotic Abyss Fredrick M. Abrahamian, D.O., FACEP, FIDSA Professor of Medicine UCLA School of Medicine Director of Education Department of Emergency Medicine Olive View-UCLA Medical Center Sylmar, California
More informationAberdeen Hospital. Antibiotic Susceptibility Patterns For Commonly Isolated Organisms For 2015
Aberdeen Hospital Antibiotic Susceptibility Patterns For Commonly Isolated s For 2015 Services Laboratory Microbiology Department Aberdeen Hospital Nova Scotia Health Authority 835 East River Road New
More information2017 Antibiogram. Central Zone. Alberta Health Services. including. Red Deer Regional Hospital. St. Mary s Hospital, Camrose
2017 Antibiogram Central Zone Alberta Health Services including Red Deer Regional Hospital St. Mary s Hospital, Camrose Introduction This antibiogram is a cumulative report of the antimicrobial susceptibility
More informationBACTERIAL SUSCEPTIBILITY REPORT: 2016 (January 2016 December 2016)
BACTERIAL SUSCEPTIBILITY REPORT: 2016 (January 2016 December 2016) VA Palo Alto Health Care System April 14, 2017 Trisha Nakasone, PharmD, Pharmacy Service Russell Ryono, PharmD, Public Health Surveillance
More informationAntibiotic Updates: Part II
Antibiotic Updates: Part II Fredrick M. Abrahamian, DO, FACEP, FIDSA Health Sciences Clinical Professor of Emergency Medicine David Geffen School of Medicine at UCLA Los Angeles, California Financial Disclosures
More informationGENERAL NOTES: 2016 site of infection type of organism location of the patient
GENERAL NOTES: This is a summary of the antibiotic sensitivity profile of clinical isolates recovered at AIIMS Bhopal Hospital during the year 2016. However, for organisms in which < 30 isolates were recovered
More informationAntimicrobial Susceptibility Patterns
Antimicrobial Susceptibility Patterns KNH SURGERY Department Masika M.M. Department of Medical Microbiology, UoN Medicines & Therapeutics Committee, KNH Outline Methodology Overall KNH data Surgery department
More informationAntimicrobial Stewardship Strategy: Antibiograms
Antimicrobial Stewardship Strategy: Antibiograms A summary of the cumulative susceptibility of bacterial isolates to formulary antibiotics in a given institution or region. Its main functions are to guide
More informationPRACTIC GUIDELINES for APPROPRIATE ANTIBIOTICS USE
PRACTIC GUIDELINES for APPROPRIATE ANTIBIOTICS USE Global Alliance for Infection in Surgery World Society of Emergency Surgery (WSES) and not only!! Aims - 1 Rationalize the risk of antibiotics overuse
More informationmicrobiology testing services
microbiology testing services You already know Spectra Laboratories for a wide array of dialysis-related testing services. Now get to know us for your microbiology needs. As the leading provider of renal-specific
More information2016 Antibiogram. Central Zone. Alberta Health Services. including. Red Deer Regional Hospital. St. Mary s Hospital, Camrose
2016 Antibiogram Central Zone Alberta Health Services including Red Deer Regional Hospital St. Mary s Hospital, Camrose Introduction This antibiogram is a cumulative report of the antimicrobial susceptibility
More informationChildrens Hospital Antibiogram for 2012 (Based on data from 2011)
Childrens Hospital Antibiogram for 2012 (Based on data from 2011) Prepared by: Department of Clinical Microbiology, Health Sciences Centre For further information contact: Andrew Walkty, MD, FRCPC Medical
More informationNorthwestern Medicine Central DuPage Hospital Antimicrobial Criteria Updated 11/16/16
Northwestern Medicine Central DuPage Hospital Antimicrobial Criteria Updated 11/16/16 These criteria are based on national and local susceptibility data as well as Infectious Disease Society of America
More informationUnderstanding the Hospital Antibiogram
Understanding the Hospital Antibiogram Sharon Erdman, PharmD Clinical Professor Purdue University College of Pharmacy Infectious Diseases Clinical Pharmacist Eskenazi Health 5 Understanding the Hospital
More informationIntrinsic, implied and default resistance
Appendix A Intrinsic, implied and default resistance Magiorakos et al. [1] and CLSI [2] are our primary sources of information on intrinsic resistance. Sanford et al. [3] and Gilbert et al. [4] have been
More informationLeveraging the Lab and Microbiology Department to Optimize Stewardship
Leveraging the Lab and Microbiology Department to Optimize Stewardship Presented by: Andrew Martinez MLS(ASCP), MT(AMT), MBA Alaska Native Medical Center Microbiology Supervisor Maniilaq Health Center
More informationCARBAPENEM RESISTANT ENTEROBACTERIACEAE (KPC CRE)
CARBAPENEM RESISTANT ENTEROBACTERIACEAE (KPC CRE) Bartsch SM et al. Potential economic burden of carbapenem-resistent Enterobacteriaceae (CRE) in the United States. Clin Microbiol Infect 2017;23(1):48e9-e16.
More informationAppropriate Management of Common Pediatric Infections. Blaise L. Congeni M.D. Akron Children s Hospital Division of Pediatric Infectious Diseases
Appropriate Management of Common Pediatric Infections Blaise L. Congeni M.D. Akron Children s Hospital Division of Pediatric Infectious Diseases It s all about the microorganism The common pathogens Viruses
More informationCF WELL Pharmacology: Microbiology & Antibiotics
CF WELL Pharmacology: Microbiology & Antibiotics Bradley E. McCrory, PharmD, BCPS Clinical Pharmacy Specialist Pulmonary Medicine Cincinnati Children s Hospital Medical Center January 26, 2017 Disclosure
More informationJump Starting Antimicrobial Stewardship
Jump Starting Antimicrobial Stewardship Amanda C. Hansen, PharmD Pharmacy Operations Manager Carilion Roanoke Memorial Hospital Roanoke, Virginia March 16, 2011 Objectives Discuss guidelines for developing
More informationOver the past several decades, the frequency of. Resistance Patterns Among Nosocomial Pathogens* Trends Over the Past Few Years. Ronald N.
Resistance Patterns Among Nosocomial Pathogens* Trends Over the Past Few Years Ronald N. Jones, MD Multiple surveillance studies have demonstrated that resistance among prevalent pathogens is increasing
More informationCONTAGIOUS COMMENTS Department of Epidemiology
VOLUME XXIX NUMBER 3 November 2014 CONTAGIOUS COMMENTS Department of Epidemiology Bugs and Drugs Elaine Dowell SM MLS (ASCP), Marti Roe SM MLS (ASCP), Sarah Parker MD, Jason Child PharmD, and Samuel R.
More informationAntibiotic. Antibiotic Classes, Spectrum of Activity & Antibiotic Reporting
Antibiotic Antibiotic Classes, Spectrum of Activity & Antibiotic Reporting Any substance of natural, synthetic or semisynthetic origin which at low concentrations kills or inhibits the growth of bacteria
More informationSimilar to Penicillins: -Chemically. -Mechanism of action. -Toxicity.
Similar to Penicillins: -Chemically. -Mechanism of action. -Toxicity. Cephalosporins are divided into Generations: -First generation have better activity against gram positive organisms. -Later compounds
More informationAntimicrobial Cycling. Donald E Low University of Toronto
Antimicrobial Cycling Donald E Low University of Toronto Bad Bugs, No Drugs 1 The Antimicrobial Availability Task Force of the IDSA 1 identified as particularly problematic pathogens A. baumannii and
More informationCipro for gram positive cocci in urine
Buscar... Cipro for gram positive cocci in urine 20-6-2017 Pneumonia can be generally defined as an infection of the lung parenchyma, in which consolidation of the affected part and a filling of the alveolar
More informationINFECTIOUS DISEASES DIAGNOSTIC LABORATORY NEWSLETTER
INFECTIOUS DISEASES DIAGNOSTIC LABORATORY NEWSLETTER University of Minnesota Health University of Minnesota Medical Center University of Minnesota Masonic Children s Hospital May 2017 Printed herein are
More informationMono- versus Bitherapy for Management of HAP/VAP in the ICU
Mono- versus Bitherapy for Management of HAP/VAP in the ICU Jean Chastre, www.reamedpitie.com Conflicts of interest: Consulting or Lecture fees: Nektar-Bayer, Pfizer, Brahms, Sanofi- Aventis, Janssen-Cilag,
More informationAntimicrobial stewardship in managing septic patients
Antimicrobial stewardship in managing septic patients November 11, 2017 Samuel L. Aitken, PharmD, BCPS (AQ-ID) Clinical Pharmacy Specialist, Infectious Diseases slaitken@mdanderson.org Conflict of interest
More informationGuidelines for the Initiation of Empirical Antibiotic therapy in Respiratory Disease (Adults)
Guidelines for the Initiation of Empirical Antibiotic therapy in Respiratory Disease (Adults) Community Acquired Community Acquired 1) Is it pneumonia? ie new symptoms and signs of a lower respiratory
More informationGuidelines for the Initiation of Empirical Antibiotic therapy in Respiratory Disease (Adults)
Guidelines for the Initiation of Empirical Antibiotic therapy in Respiratory Disease (Adults) Community Acquired Pneumonia Community Acquired Pneumonia 1) Is it pneumonia? ie new symptoms and signs of
More informationESISTONO LE HCAP? Francesco Blasi. Sezione Medicina Respiratoria Dipartimento Toraco Polmonare e Cardiocircolatorio Università degli Studi di Milano
ESISTONO LE HCAP? Francesco Blasi Sezione Medicina Respiratoria Dipartimento Toraco Polmonare e Cardiocircolatorio Università degli Studi di Milano Community-acquired pneumonia (CAP): Management issues
More informationDr. Shaiful Azam Sazzad. MD Student (Thesis Part) Critical Care Medicine Dhaka Medical College
Dr. Shaiful Azam Sazzad MD Student (Thesis Part) Critical Care Medicine Dhaka Medical College INTRODUCTION ICU acquired infection account for substantial morbidity, mortality and expense. Infection and
More informationCost high. acceptable. worst. best. acceptable. Cost low
Key words I Effect low worst acceptable Cost high Cost low acceptable best Effect high Fig. 1. Cost-Effectiveness. The best case is low cost and high efficacy. The acceptable cases are low cost and efficacy
More informationNational Surveillance of Antimicrobial Resistance in Pseudomonas aeruginosa Isolates Obtained from Intensive Care Unit Patients from 1993 to 2002
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Dec. 2004, p. 4606 4610 Vol. 48, No. 12 0066-4804/04/$08.00 0 DOI: 10.1128/AAC.48.12.4606 4610.2004 Copyright 2004, American Society for Microbiology. All Rights
More information9/30/2016. Dr. Janell Mayer, Pharm.D., CGP, BCPS Dr. Lindsey Votaw, Pharm.D., CGP, BCPS
Dr. Janell Mayer, Pharm.D., CGP, BCPS Dr. Lindsey Votaw, Pharm.D., CGP, BCPS 1 2 Untoward Effects of Antibiotics Antibiotic resistance Adverse drug events (ADEs) Hypersensitivity/allergy Drug side effects
More informationInteractive session: adapting to antibiogram. Thong Phe Heng Vengchhun Felix Leclerc Erika Vlieghe
Interactive session: adapting to antibiogram Thong Phe Heng Vengchhun Felix Leclerc Erika Vlieghe Case 1 63 y old woman Dx: urosepsis? After 2 d: intermediate result: Gram-negative bacilli Empiric antibiotic
More informationAntibiotic Stewardship Program (ASP) CHRISTUS SETX
Antibiotic Stewardship Program (ASP) CHRISTUS SETX Program Goals I. Judicious use of antibiotics Decrease use of broad spectrum antibiotics and deescalate use based on clinical symptoms Therapeutic duplication:
More informationBai-Yi Chen MD. FCCP
Treatment strategies for hospitalized versus nonhospitalized CAP patients: Asian perspective Bai-Yi Chen MD. FCCP Professor of Medicine Division of Infectious Disease, Infection Control Team The First
More informationSafe Patient Care Keeping our Residents Safe Use Standard Precautions for ALL Residents at ALL times
Safe Patient Care Keeping our Residents Safe 2016 Use Standard Precautions for ALL Residents at ALL times #safepatientcare Do bugs need drugs? Dr Deirdre O Brien Consultant Microbiologist Mercy University
More informationLearning Points. Raymond Blum, M.D. Antimicrobial resistance among gram-negative pathogens is increasing
Raymond Blum, M.D. Learning Points Antimicrobial resistance among gram-negative pathogens is increasing Infection with antimicrobial-resistant pathogens is associated with increased mortality, length of
More informationNEW ATS/IDSA VAP-HAP GUIDELINES
NEW ATS/IDSA VAP-HAP GUIDELINES MARK L. METERSKY, MD PROFESSOR OF MEDICINE UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE FARMINGTON, CT Mark Metersky, MD, FCCP, FACP is a Professor of Medicine at the University
More informationDuke University Hospital Guideline for Empiric Inpatient Treatment of Cancer- Related Neutropenic Fever in Adult Patients
Duke University Hospital Guideline for Empiric Inpatient Treatment of Cancer- Related Neutropenic Fever in Adult Patients PURPOSE Fever among neutropenic patients is common and a significant cause of morbidity
More informationDetection and Quantitation of the Etiologic Agents of Ventilator Associated Pneumonia in Endotracheal Tube Aspirates From Patients in Iran
Letter to the Editor Detection and Quantitation of the Etiologic Agents of Ventilator Associated Pneumonia in Endotracheal Tube Aspirates From Patients in Iran Mohammad Rahbar, PhD; Massoud Hajia, PhD
More informationKonsequenzen für Bevölkerung und Gesundheitssysteme. Stephan Harbarth Infection Control Program
Konsequenzen für Bevölkerung und Gesundheitssysteme Stephan Harbarth Infection Control Program University of Geneva Hospitals Outline Introduction What data sources are available? AMR-associated outcomes
More informationNQF-ENDORSED VOLUNTARY CONSENSUS STANDARDS FOR HOSPITAL CARE. Measure Information Form Collected For: CMS Voluntary Only
Last Updated: Version 4.4a NQF-ENDORSED VOLUNTARY CONSENSUS STANDARDS FOR HOSPITAL CARE Measure Set: Pneumonia (PN) Performance Measure Identifier: Measure Information Form Collected For: CMS Voluntary
More informationIntra-Abdominal Infections. Jessica Thompson, PharmD, BCPS (AQ-ID) Infectious Diseases Pharmacy Clinical Specialist Renown Health April 19, 2018
Intra-Abdominal Infections Jessica Thompson, PharmD, BCPS (AQ-ID) Infectious Diseases Pharmacy Clinical Specialist Renown Health April 19, 2018 Select guidelines Mazuski JE, et al. The Surgical Infection
More informationPrevalence of Metallo-Beta-Lactamase Producing Pseudomonas aeruginosa and its antibiogram in a tertiary care centre
International Journal of Current Microbiology and Applied Sciences ISSN: 2319-7706 Volume 4 Number 9 (2015) pp. 952-956 http://www.ijcmas.com Original Research Article Prevalence of Metallo-Beta-Lactamase
More informationStanding Orders for the Treatment of Outpatient Peritonitis
Standing Orders for the Treatment of Outpatient Peritonitis 1. Definition of Peritonitis: a. Cloudy effluent. b. WBC > 100 cells/mm3 with >50% polymorphonuclear (PMN) cells with minimum 2 hour dwell. c.
More informationQUICK REFERENCE. Pseudomonas aeruginosa. (Pseudomonas sp. Xantomonas maltophilia, Acinetobacter sp. & Flavomonas sp.)
Pseudomonas aeruginosa (Pseudomonas sp. Xantomonas maltophilia, Acinetobacter sp. & Flavomonas sp.) Description: Greenish gray colonies with some beta-hemolysis around each colony on blood agar (BAP),
More information11/10/2016. Skin and Soft Tissue Infections. Disclosures. Educational Need/Practice Gap. Objectives. Case #1
Disclosures Selecting Antimicrobials for Common Infections in Children FMR-Contemporary Pediatrics 11/2016 Sean McTigue, MD Assistant Professor of Pediatrics, Pediatric Infectious Diseases Medical Director
More informationPrinciples of Infectious Disease. Dr. Ezra Levy CSUHS PA Program
Principles of Infectious Disease Dr. Ezra Levy CSUHS PA Program I. Microbiology (1) morphology (e.g., cocci, bacilli) (2) growth characteristics (e.g., aerobic vs anaerobic) (3) other qualities (e.g.,
More informationStanding Orders for the Treatment of Outpatient Peritonitis
Standing Orders for the Treatment of Outpatient Peritonitis 1. Definition of Peritonitis: a. Cloudy effluent. b. WBC > 100 cells/mm3 with >50% polymorphonuclear (PMN) cells with minimum 2 hour dwell. c.
More informationFlorida Health Care Association District 2 January 13, 2015 A.C. Burke, MA, CIC
Florida Health Care Association District 2 January 13, 2015 A.C. Burke, MA, CIC 11/20/2014 1 To describe carbapenem-resistant Enterobacteriaceae. To identify laboratory detection standards for carbapenem-resistant
More informationPneumonia. Community Acquired Pneumonia (CAP): definition. At least 2 new symptoms
Pneumonia Lisa G. Winston, MD University of California, San Francisco San Francisco General Hospital Community Acquired Pneumonia (CAP): definition At least 2 new symptoms Fever or hypothermia Cough Rigors
More informationCommunity Acquired Pneumonia. Epidemiology: Acute Lower Respiratory Tract Infections. Community Acquired Pneumonia (CAP) Outline
Community Acquired Pneumonia (CAP) Outline Lisa G. Winston, MD University of California, San Francisco Zuckerberg San Francisco General Epidemiology Diagnosis Microbiology Risk stratification Treatment
More informationANTIBIOTIC STEWARDSHIP
ANTIBIOTIC STEWARDSHIP S.A. Dehghan Manshadi M.D. Assistant Professor of Infectious Diseases and Tropical Medicine Tehran University of Medical Sciences Issues associated with use of antibiotics were recognized
More informationNational Surveillance of Antimicrobial Resistance
National Surveillance of Antimicrobial Resistance Report to Ministry of Health by Sri Lanka College of Microbiologists SLCM ARSP & NLBSA Technical Committees December 2014 National Surveillance of Antimicrobial
More informationCombination vs Monotherapy for Gram Negative Septic Shock
Combination vs Monotherapy for Gram Negative Septic Shock Critical Care Canada Forum November 8, 2018 Michael Klompas MD, MPH, FIDSA, FSHEA Professor, Harvard Medical School Hospital Epidemiologist, Brigham
More informationPIPERACILLIN- TAZOBACTAM INJECTION - SUPPLY PROBLEMS
PIPERACILLIN- TAZOBACTAM INJECTION - SUPPLY PROBLEMS The current supply of piperacillin- tazobactam should be reserved f Microbiology / Infectious Diseases approval and f neutropenic sepsis, severe sepsis
More informationHealth Care-Associated Pneumonia and Community-Acquired Pneumonia: a Single-Center Experience
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Oct. 2007, p. 3568 3573 Vol. 51, No. 10 0066-4804/07/$08.00 0 doi:10.1128/aac.00851-07 Copyright 2007, American Society for Microbiology. All Rights Reserved. Health
More information